Journal
ACS CHEMICAL NEUROSCIENCE
Volume 9, Issue 4, Pages 817-823Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.7b00439
Keywords
Synergistic inhibitory effect; cytotoxicity; amyloid beta (A beta) peptide; graphene quantum dots (GQDs); tramiprosate
Funding
- National Natural Science Foundation of China (NSFC) [21475009, 21475008]
- Beijing Municipal Science & Technology Commission [Z161100000116037]
Ask authors/readers for more resources
Inhibiting the amyloid aggregation is considered to be an effective strategy to explore possible treatment of amyloid-related diseases including Alzheimer's disease, Parkinson's disease, and type II diabetes. Herein, a new high-efficiency and low-cytotoxicity A beta aggregation inhibitors, GQD-T, was designed through the combination of two A beta aggregation inhibitors, graphene quantum dots (GQDs) and tramiprosate. GQD-T showed the capability of efficiently inhibiting the aggregation of A beta peptides and rescuing A beta-induced cytotoxicity due to the synergistic effect of the GQDs and tramiprosate. In addition, the GQD-T has the characteristics of low toxicity and great biocompatibility. It is believed that GQD-T may be a potential candidate for an Alzheimer's drug and this work provides a new strategy for exploring A beta peptide aggregation inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available